Our Product – UbiHealth
Our first product will be a hand-held respiratory viral test panel, enabling at home molecular detection and multiplexed identification of Flu-A/B/RSV/SARS-CoV-2 from a self-collected saliva sample, achieving portable state-of-the-art sensitivity and specificity.
In the emerging era of “test-and-treat” and “test-at-home” policies, UbiHealth will facilitate decentralisation of healthcare and enable many new benefits in point-of-care and in home telemedicine.
Our first product will be a hand-held respiratory viral test panel, enabling at home molecular detection and multiplexed identification of Flu-A/B/RSV/SARS-CoV-2 from a self-collected saliva sample, achieving portable state-of-the-art sensitivity and specificity.
The safe sealed test cartridge will eliminate the risks due to sample handling and shipping to laboratories. Self-tests for HIV-Viral Load and other infectious diseases and pathogens will follow. Immediate encrypted digital wireless upload of results will enable realtime epidemiological tracking.
In the emerging era of “test-and-treat” and “test-at-home” policies, UbiHealth will facilitate decentralisation of healthcare and enable many new benefits in point-of-care and in home telemedicine.
